Rockefeller Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Rockefeller Capital Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$96.7K	Buy	884 +257	+41%	+$26.6K	﹤0.01%	3006
2026 Q1	$65.1K	Buy	627 +352	+128%	+$37.5K	﹤0.01%	3128
2025 Q4	$28.4K	Sell	275 -4,630	-94%	-$450K	﹤0.01%	3350
2025 Q3	$443K	Buy	+4,905	New	+$430K	﹤0.01%	1829
2023 Q1	–	Sell	-1,300	Closed	-$101K	–	3398
2022 Q4	$101K	Hold	1,300	–	–	﹤0.01%	2020
2022 Q3	$87K	Hold	1,300	–	–	﹤0.01%	2065
2022 Q2	$99K	Buy	+1,300	New	+$101K	﹤0.01%	1954

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Rockefeller Capital Management's PPH Position: Q2 2026 in Review

Rockefeller Capital Management increased its VanEck Pharmaceutical ETF (PPH) stake by 41% in Q2 2026, buying an estimated $26.6K and bringing the position to 884 shares worth $96.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3006.

Rockefeller Capital Management first reported a position in PPH in Q2 2022 and has held it in 7 quarters since. The position peaked at $443K in Q3 2025. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Rockefeller Capital Management held 884 shares of VanEck Pharmaceutical ETF worth $96.7K as of Q2 2026.
Rockefeller Capital Management bought 257 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $26.6K.
VanEck Pharmaceutical ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3006 holding.
Rockefeller Capital Management first reported a position in VanEck Pharmaceutical ETF in Q2 2022 and has held it in 7 quarters since.
Rockefeller Capital Management's VanEck Pharmaceutical ETF position peaked at $443K in Q3 2025.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.